The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -160,416 |
| Stock-based compensation | 142,435 |
| Prepaid expenses | 586 |
| Other assets | -9,851 |
| Accounts payable | 2,145 |
| Accrued expenses | 704 |
| Net cash used in operating activities | -5,867 |
| Proceeds from business combination | 27 |
| Proceeds from related party loan | 5,848 |
| Net cash provided by financing activities | 5,875 |
| Net change in cash and cash equivalents | 8 |
| Cash and cash equivalents at beginning of period | 12 |
| Cash and cash equivalents at end of period | 20 |
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)